Page last updated: 2024-11-07

1-aminoindan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID123445
CHEMBL ID158574
SCHEMBL ID6600
SCHEMBL ID12787610
MeSH IDM0067417

Synonyms (72)

Synonym
AC-3212
34698-41-4
EN300-24105
BB 0254610
1-aminoindan
1h-inden-1-amine, 2,3-dihydro-, (.+/-.)-
1-aminoindane
NCIOPEN2_000245
61949-83-5
nsc-62540
nsc62540
inchi=1/c9h11n/c10-9-6-5-7-3-1-2-4-8(7)9/h1-4,9h,5-6,10h
1-aminoindan, 98%
STK503761
2,3-dihydro-1h-inden-1-amine
1-indanamine
A1309
indan-1-ylamine
FT-0693415
1h-inden-1-amine, 2,3-dihydro-, (+-)-
CHEMBL158574
AKOS001276620
A833501
A25664
2,3-dihydro-1h-inden-1-ylamine;1-aminohydrindene
NCGC00184208-01
nsc 62540
2,3-dihydro-1h-inden-1-ylamine
2,3-dihydro-1h-inden-1-yl-amine
8up8m3cgs8 ,
einecs 252-158-7
unii-8up8m3cgs8
BP-10472
FT-0607349
FT-0605032
FT-0605238
indanylamine
AB04893
AB00328
AB04896
AKOS016050360
SCHEMBL6600
indan-1-amine
indanamine
(-)-1-aminoindane
(+/-)-1-aminoindan
racemic 1-aminoindan
racemic 1-aminoindane
rac-1-aminoindane
(+/-)-1-aminoindane
aminoindan
(rac)-1-aminoindan
1-amino-indane
SCHEMBL12787610
1h-inden-1-amine, 2,3-dihydro-
1-indanamine #
W-202423
STR03738
1h-indenamine, 2,3-dihydro-
1-aminoindan;
mfcd00003799
CS-W007551
(?)-1-aminoindan
BCP21794
(-)-1-aminoindan pound>>1-aminoindan, (-)-
SY004953
1-phenylaminocyclopentanecarboxylicacid
DTXSID20902754
( r)-1-aminoindane
SY007171
SY007172
Z168884748
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency35.48130.000811.382244.6684AID686978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1199588Cytotoxicity against metabolically competent immortalized TNFalpha overexpressing mouse hepatocytes assessed as cell viability at 100 microM after 24 hrs by MTT assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1199589Cytotoxicity against metabolically competent immortalized TNFalpha overexpressing mouse hepatocytes assessed as cell viability at 10 microM after 24 hrs by MTT assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1199591Cytotoxicity against metabolically competent immortalized TNFalpha overexpressing mouse hepatocytes assessed as cell viability at 10 microM after 72 hrs by MTT assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1199590Cytotoxicity against metabolically competent immortalized TNFalpha overexpressing mouse hepatocytes assessed as cell viability at 100 microM after 72 hrs by MTT assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (11.76)18.7374
1990's0 (0.00)18.2507
2000's5 (29.41)29.6817
2010's8 (47.06)24.3611
2020's2 (11.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.70 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index25.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]